Literature DB >> 3456283

Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.

H Schrøder, N Clausen, E Ostergaard, T Pressler.   

Abstract

The concentration of methotrexate (MTX) in erythrocytes (E-MTX) was measured in 47 children with acute lymphoblastic leukemia during maintenance treatment with MTX 1.7-21.6 mg/m2/week and 6-mercaptopurine 25-75 mg/m2/day. At the time of measurement the plasma MTX concentration was less than 2 nmol/l. The steady state E-MTX varied between 51 and 202 nmol/l erythrocytes. Alterations in the E-MTX took place over 8-12 weeks after a change in dosage. A significant correlation was found between the E-MTX and the weekly dose of MTX administered. Noncompliance was revealed in two patients. A very low E-MTX was found in one patients, probably caused by inhibition of erythropoiesis. No correlation was found between E-MTX and the total amount of MTX administered or the length of treatment. A terminal half-life of 2-5 weeks after discontinuation of the drug showed that the erythrocytes functioned as a slow-changing compartment for MTX. Unexpectedly low E-MTX could mean noncompliance, impaired erythropoiesis, altered metabolism, or poor drug absorption.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456283     DOI: 10.1007/BF00256175

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  A rapid, radiochemical-ligand binding assay for methotrexate.

Authors:  B A Kamen; P L Takach; R Vatev; J D Caston
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

2.  Pharmacokinetics of methotrexate in erythrocytes in psoriasis.

Authors:  J Hendel; A Nyfors
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Separation and identification of subpicomole amounts of methotrexate polyglutamates in animal and human biopsy material.

Authors:  G R Krakower; P A Nylen; B A Kamen
Journal:  Anal Biochem       Date:  1982-05-15       Impact factor: 3.365

4.  Characteristics of methotrexate polyglutamate formation in cultured hepatic cells.

Authors:  M Balinska; Z Nimec; J Galivan
Journal:  Arch Biochem Biophys       Date:  1982-07       Impact factor: 4.013

Review 5.  Methotrexate therapy of psoriasis. Effect and side effects with particular reference to hepatic changes. A survey.

Authors:  A Nyfors
Journal:  Dan Med Bull       Date:  1980-04

6.  Pharmacokinetics of oral methotrexate in children.

Authors:  F M Balis; J L Savitch; W A Bleyer
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

7.  Methotrexate and folate content of erythrocytes in patients receiving oral vs intramuscular therapy with methotrexate.

Authors:  B A Kamen; J S Holcenberg; K Turo; V M Whitehead
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

8.  Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.

Authors:  J Jolivet; R L Schilsky; B D Bailey; J C Drake; B A Chabner
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

9.  Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug.

Authors:  B A Kamen; P A Nylen; B M Camitta; J R Bertino
Journal:  Br J Haematol       Date:  1981-11       Impact factor: 6.998

10.  Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate.

Authors:  A Schalhorn; H Sauer; W Wilmanns; G Stupp-Poutot
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more
  14 in total

1.  Removal of methotrexate by hemodiafiltration.

Authors:  N Montagne; G Milano; C Caldani; J Bracco; P Ayela; E Cassuto; A Thyss; M Schneider
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Wanda L Salzer; Naomi J Winick; Pierre Wacker; Xiaomin Lu; Meenakshi Devidas; Jonathan J Shuster; Donald H Mahoney; Stephen J Lauer; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2012-01       Impact factor: 1.289

3.  The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.

Authors:  P Seideman; O Beck; S Eksborg; M Wennberg
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

4.  Methotrexate in erythrocytes of patients with psoriasis.

Authors:  H Schrøder; E K Foged
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Methotrexate in neutrophils in children with acute lymphoblastic leukemia.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Methotrexate pharmacokinetics in age-fractionated erythrocytes.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study.

Authors:  M L Graham; J J Shuster; B A Kamen; D L Cheo; M P Harrison; B G Leventhal; D J Pullen; V M Whitehead
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.

Authors:  K Schmiegelow; I Bruunshuus
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.

Authors:  H Schrøder; K Fogh; T Herlin
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.

Authors:  H Schrøder; K Fogh
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.